Atlas Trials

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

Clinical trial NCT05562024 · RECRUITING

Trial details

NCT number
NCT05562024
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
B7-H3-positive Relapsed/ Refractory Neuroblastoma
Start date
2022-12-30
Primary completion
2025-12-18
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.